Clinical Trial Update: Radiation Use During Vemurafenib Treatment [Phase 1]

View source ↗

Summary

A Phase I trial investigating the use of radiation during vemurafenib treatment for BRAFV600 mutation-associated Stage IV melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Sponsor: University of Utah | Conditions: BRAFV600 Mutation, Stage IV Melanoma | Phase 1 | Status: WITHDRAWN